


Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula I



(I)

or a pharmaceutically acceptable salt thereof;

wherein R1 is H, methyl or ethyl; R2 is H or phenyl and


B is

1) $-(CH_2)_3NHC(NH)NH_2$,

2) $-(CH_2)_3NH_2$,

3) $-(CH_2)_2NH_2$ or


4)




wherein asterisk (*) indicates the point of attachment;

with the proviso that when B is $-(CH_2)_3NHC(NH)NH_2$, then R1 is not hydrogen.


2. (Original) A compound of claim 1 whereby the compound has the structure




3. (Original) A compound of claim 1 whereby the compound has the structure




4. (Original) A compound of claim 1 whereby the compound has the structure




5. (Original) A compound of claim 1 whereby the compound has the structure




6. (Original) A compound of claim 1 whereby the compound has the structure




7. (Original) A compound of claim 1 whereby the compound has the structure



8. (Original) A compound of claim 1 whereby the compound has the structure



9. (Original) A compound of claim 1 whereby the compound has the structure



10. (Currently Amended) A pharmaceutical composition comprising of a compound according to ~~any of claims 1 to 9~~claim 1 as an active ingredient together with a pharmaceutically acceptable diluent, carrier and/or excipient.

11. (Currently Amended) ~~The use of a compound of any of claims 1 to 9, or a pharmaceutically acceptable salt thereof,~~A method for the preparation of a medicament for treating a disease or condition in mammals where interaction with the somatostatin receptor subtype 4 optionally together with the subtype 1 is indicated to be useful, comprising mixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent, carrier and/or excipient.